ArticleBMC medicine2017
When is proton pump inhibitor use appropriate?
Article in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Pooled it
- Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis.Hepatology international · 2020Pooled it
- Herbal and Natural Product Interventions to Modulate Gut Microbiota in Acid Suppression-Associated Dysbiosis: a systematic review protocol.Journal of pharmacopuncture · 2026Article
- Analysis of proton pump inhibitor-associated drug problems and contributing factors among hospitalized nephrology patients.Frontiers in pharmacology · 2026Article
- Artificial intelligence-assisted quality control circles led by clinical pharmacists to improve the rational use of parenteral proton pump inhibitors among hospitalised patients.Scientific reports · 2025Article
- Proton pump inhibitors and mortality in patients with cancer: Unraveling the complex link.World journal of clinical oncology · 2025Article
- Predictive Factors Associated with Inappropriate Intravenous Proton Pump Inhibitors Use in Hospitalized Patients: A Case-Control Study.Medicina (Kaunas, Lithuania) · 2024Article
- Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks.Current gastroenterology reports · 2024Review
- Epidemiology and Healthcare Service Utilization among Adults with Chronic Cough.Journal of clinical medicine · 2024Article
- Use of potentially inappropriate medication for elderly patients in tertiary care hospital of Riyadh, Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Proton Pump Inhibitors: Rational Use and Use-Reduction - The Windsor Workshop.Digestive diseases (Basel, Switzerland) · 2024Review
- Gastric development of pancreatic acinar cell metaplasia after Vonoprazan therapy in rats.Surgical endoscopy · 2023Article
- Mechanisms of proton pump inhibitor-induced hypomagnesemia.Acta physiologica (Oxford, England) · 2022Review
- The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis.Frontiers in immunology · 2022Article
- Massive pleural effusion following high-power and short-duration radiofrequency ablation for treatment of atrial fibrillation: A case report and review of the literature.Frontiers in cardiovascular medicine · 2022Article
- Lack of association between proton pump inhibitor use and decline in cognitive performance in the ELSA-Brasil cohort.European journal of clinical pharmacology · 2021Article
- Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome.Nature communications · 2021Article
- Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis.Therapeutic advances in gastroenterology · 2021Article
- Pericarditis and Post-cardiac Injury Syndrome as a Sequelae of Acute Myocardial Infarction.Current cardiology reports · 2020Review
- The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study.PLoS medicine · 2020Observational
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time, data suggesting adverse effects of long-term PPI therapy are multiplying, albeit mainly from low quality studies. The systematic review by Scarpignato et al. (BMC Med 14:179, 2016) addresses this dilemma with a comprehensive analysis of the risks and benefits of PPI use. The authors concluded that, while PPIs are highly efficacious in erosive acid-peptic disorders, efficacy is not equaled in other conditions. In some instances, they found no supportive evidence of benefit. With respect to side effects, they indicated that the questionable harms associated with PPI therapy do not outweigh the benefits afforded by appropriate PPI use. However, inappropriate PPI use results in increased healthcare costs and unnecessary exposure to potential adverse effects. Ideally, PPI therapy should be personalized, based on indication, effectiveness, patient preference, and risk assessment.Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0718-z .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.